These data strengthen the evidence indicating that Omomyc represents a common inhibitor for the interaction of MAX with all MYC proteins in vivo and further supports the utility of Omomyc as a therapeutic strategy for SCLC. The gene discussed is MYC; the disease is small cell lung carcinoma.